DDX41 and neoplasm: Using an immunocompetent mouse model humanized for both CD40 and all human FcγRs (hCD40/hFcγR mice), we demonstrated that 2141-V11 has enhanced immune stimulatory activity in vivo, resulting in enhanced DC activation and CD8 anti-tumor immunity when compared to other clinical CD40 Abs lacking selective FcγRIIB binding across several tumor models15.